MedTrace Logo

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

NCT02500667 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-11-07

No results posted yet for this study

Summary

The present study is designed to assess the effects of Rifampin on the pharmacokinetics of N91115 in healthy subjects.

Conditions

  • Drug Interaction Potentiation

Interventions

DRUG

N91115

200 mg BID

DRUG

Rifampin

600 mg QD

Sponsors & Collaborators

  • Davita Clinical Research

    collaborator INDUSTRY

  • Nivalis Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher Galloway, MD · Davita Clinical Research

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500667 on ClinicalTrials.gov